ClinicalTrials.gg
RecruitingNCT06503692DKTAVGUpdated Jan 9, 2025

Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis

An interventional study of DKutting PTA Scoring Balloon Dilatation Catheter and Peripheral Balloon Catheter in Arteriovenous Graft Stenosis, sponsored by DK Medical Technology (Suzhou) Co., Ltd.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-09.

Sponsored by DK Medical Technology (Suzhou) Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.

Planned enrollment
29th of 56
140 · median 145
Started
2024
with 11 others
No phase
48 of 81
21 open now
Primary completion
2026-12
later than 17 of 39 live
Registered
56th of 81
by date
Lead sponsor
3 of 81
DK Medical Technology (Suzhou) Co., Ltd.

Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 29th largest by planned enrollment of the 56 interventional ones that give a count, is one of 12 that started in 2024, is one of 48 with no phase, reaches primary completion later than 17 of the 39 other live ones, and was the 56th registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Constriction, Pathologic with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, prospective, randomized controlled clinical study. Patients with hemodialysis arteriovenous graft fistula stenosis will be recruited to explore whether the scoring balloon is superior to the high pressure balloon in treating such lesions, so as to provide a basis for optimizing the treatment of such lesions.

This study will be conducted in seven (7) clinical trial institutions, with a total of 140 subjects included. After randomization, the subjects will use either the scoring balloon dilatation catheter, developed and produced by DK Medical Technology Co., Ltd., or the peripheral balloon dilatation catheter for surgical treatment. Clinical follow-up will be carried out within 5 days, 3 months, 6 months, and 12 months after the procedure.

03

Conditions studied

  • Arteriovenous Graft Stenosis

Keywords

  • Arteriovenous Graft Stenosis
  • Scoring Balloon
  • Angioplasty
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hemodialysis patients aged ≥18 and ≤80 years old, (Note: Hemodialysis patients in Singapore aged ≥ 21 and ≤80 years old);
  2. AVG is mature and has successfully completed at least one hemodialysis treatment;
  3. The target lesion is located in the AVG return vein and the venous side anastomosis;
  4. The degree of stenosis of the target lesion is ≥50% (DSA visual inspection), and one of the following clinical indicators exists at the same time: Physical examination abnormalities include: open collateral veins, ipsilateral limb edema, changes in pulse characteristics, abnormal tremors, abnormal murmurs, etc.; Dialysis abnormalities include: increased venous pressure, new puncture difficulties, aspiration of thrombi, inability to reach target dialysis blood flow, prolonged haemostasis time after needle removal for 3 consecutive times, unexplained decrease in dialysis dose Kt/V (>0.2 units), decrease in brachial artery blood flow (brachial artery blood flow \<650ml/min or decreased by 20% compared with the previous follow-up visit), etc.
  5. The target lesion is primary or restenotic, consisting of one or more series of lesions, and the reference blood vessel diameter of the target lesion is between 4.0-8.0mm, and the total length of the target lesion is ≤80mm ;
  6. The patient voluntarily signs the form.

Exclusion criteria

Exclusion Criteria:

  1. The target lesion is located in the feeding artery, arterial anastomosis, artificial blood vessel puncture site, cephalic venous arch, thoracic outlet or central vein;
  2. A stent has been implanted in any part of the access or there is ipsilateral central vein stenosis or occlusion that affects the function of the access;
  3. Severely calcified lesions that are not expected to be dilatable with balloons;
  4. Acute thrombosis or chronic total occlusion of AVG occurred at the time of enrolment;
  5. The target lesion or any part of the vascular access has received PTA treatment within the last month;
  6. There are thicker branch veins in the vein opening of the end-to-side anastomosis;
  7. Patients who have undergone major surgical treatment within 30 days before inclusion in the study;
  8. Patients known to be allergic to or intolerant to contrast media;
  9. Patients receiving or ;
  10. The patient's is less than 1 year;
  11. Patients planning kidney transplantation or switching to peritoneal dialysis;
  12. The degree of stenosis in the puncture point area is >50%;
  13. Patients with infection or other medical conditions that make the investigator think they are not suitable to participate in this study;
  14. Those who have participated in clinical trials of other drugs or devices but have not completed them.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    DKutting PTA Scoring Balloon Dilatation Catheter

    Subjects in this group are treated with DKutting PTA Scoring Balloon Dilatation Catheter

    Device: DKutting PTA Scoring Balloon Dilatation Catheter

  • Active comparator
    Peripheral Balloon Catheter

    Subjects in this group are treated with Peripheral Balloon Catheter

    Device: Peripheral Balloon Catheter

Interventions

  • DeviceDKutting PTA Scoring Balloon Dilatation Catheter

    The device consists of a balloon catheter with scoring elements (triangular cross-section) fixed to the surface of the balloon and distributed radially at every 120°. When the balloon is inflated, the expansion force is focused along the scoring elements, causing it to expand under lower balloon pressure.

    Also known as: Scoring Balloon

  • DevicePeripheral Balloon Catheter

    The device is an over-the-wire (OTW) double-lumen balloon catheter. The balloon is inflated to a known diameter at a specified pressure.

06

What researchers measure

Primary outcomes

  1. Target Lesion Primary Patency (TLPP) at 6 months post-procedure

    TLPP is terminated by postoperative target lesion failure (TLF) (including the 5 mm range before and after the target lesion) or target lesion-related vascular access thrombosis. TLF is defined as the presence of at least one clinical indicator (defined according to the NKF-K/DOQI guidelines) caused by target lesion stenosis ( ≥50% stenosis of the target lesion assessed by contrast angiography or ultrasound), including physical examination abnormalities or dialysis abnormalities. Target lesion-related vascular access thrombosis is limited to: after the thrombus is removed during AVG thrombus treatment and before balloon dilatation, it is confirmed by ultrasound/DSA that the original target lesion has a stenosis ≥ 50%, or when the balloon is expanded with low pressure (\<6 atm) during intraluminal treatment, obvious balloon residual waisting can be seen at the target lesion; simple mural thrombus at the puncture point or other parts of the graft needs to be ruled out.

    Time frame: 6 months

Secondary outcomes

  1. Target Lesion Primary Patency (TLPP) at 12 months post-procedure

    TLPP is terminated by postoperative target lesion failure (TLF) (including the 5 mm range before and after the target lesion) or target lesion-related vascular access thrombosis. TLF is defined as the presence of at least one clinical indicator (defined according to the NKF-K/DOQI guidelines) caused by target lesion stenosis ( ≥50% stenosis of the target lesion assessed by contrast angiography or ultrasound), including physical examination abnormalities or dialysis abnormalities. Target lesion-related vascular access thrombosis is limited to: after the thrombus is removed during AVG thrombus treatment and before balloon dilatation, it is confirmed by ultrasound/DSA that the original target lesion has a stenosis ≥ 50%, or when the balloon is expanded with low pressure (\<6 atm) during intraluminal treatment, obvious balloon residual waisting can be seen at the target lesion; simple mural thrombus at the puncture point or other parts of the graft needs to be ruled out.

    Time frame: 12 months

  2. Access Circuit Primary Patency (ACPP) at 6 and 12 months post-procedure

    ACPP is terminated when stenosis or thrombus causing abnormal clinical indicators occurs in any part of the AVG after surgery (inflow artery, entire graft, and outflow vein, including central vein). (Definition according to NKF- K/DOQI guidelines), including physical examination abnormalities or dialysis abnormalities. Physical examination abnormalities include: open collateral veins, ipsilateral limb edema, changes in pulse characteristics, abnormal tremors, abnormal murmurs, etc.; Dialysis abnormalities include: increased venous pressure, new puncture difficulties, aspiration of thrombi, inability to reach target dialysis blood flow, prolonged haemostasis time after needle removal for 3 consecutive times, unexplained decrease in dialysis dose Kt/V (\>0.2 units), decrease in brachial artery blood flow (brachial artery blood flow \<650ml/min or decreased by 20% compared with the previous follow-up visit), etc.

    Time frame: 6, 12 months post-procedure

  3. Access Circuit Secondary Patency (ACSP) 6 and 12 months after surgery

    ACSP terminates when the AVG is abandoned due to various reasons after surgery, during which multiple interventions can be performed to maintain the patency of the entire pathway.

    Time frame: 6, 12 months post-procedure

  4. Acute Lumen Gain

    Immediately after dilation, DSA uses two different angles (≥45°) for angiography (a unified x-ray ruler will be provided as the reference object to reduce measurement errors) Calculation formula: minimum lumen diameter of the target lesion immediately after dilation - minimum lumen diameter of the target lesion before procedure.

    Time frame: During the procedure

  5. Technical Success

    Residual stenosis of the target lesion after surgery is ≤30%, and no serious adverse events related to the investigational device occurred during the perioperative period.

    Time frame: 0-5 days post-procedure

  6. Clinical Success

    Complete at least one successful hemodialysis session after surgery

    Time frame: 0-5 days post-procedure

07

Study locations

1 of 7 sites recruiting
  • Beijing Tongren Hospital Affiliated to Capital Medical University
    Beijing, Beijing, China
    Not yet recruiting
    • Zhengya Yu, MD · Contact
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Zhiming Ye, MD · Contact
  • South China Hospital of Shenzhen University
    Shenzhen, Guangdong, China
    Not yet recruiting
    • Yangdong Liu, MD · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
    Not yet recruiting
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
    Not yet recruiting
    • Hong Ye, MD · Contact
  • Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
    Shanghai, Shanghai, China
    Recruiting
    • Yaxue Shi, MD · Contact
  • National University Hospital of Singapore
    Singapore, Singapore
    Not yet recruiting
    • Jackie Ho Pei, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 28 months is below that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 16, 2024
StartActual
Aug 13, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06503692
Lead sponsor
DK Medical Technology (Suzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
Aug 13, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 9, 2025

Study contacts

Pei Wang, MD
Contact
wangpei146@hotmail.com
+86 13523467291
Pei Wang, MD
principal investigator · The First Affiliated Hospital of Zhengzhou University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion